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Background: Fatigue is a common side effect of conventional prostate cancer radiation
therapy. The increased delivery precision necessitated by the high dose per fraction of
stereotactic body radiation therapy (SBRT) offers the potential of reduce target volumes
and hence the exposure of normal tissues to high radiation doses. Herein, we examine the
level of fatigue associated with SBRT treatment. Methods: Forty patients with localized
prostate cancer treated with hypofractionated SBRT, and a minimum of 12 months follow-
up were included in this analysis. Self-reported fatigue and other quality of life measures
were assessed at baseline and at 1, 3, 6, 9, and 12 months post-SBRT. Results: Mean lev-
els of fatigue were elevated at 1 month post-SBRT compared to baseline values (P =0.02).
Fatigue at the 3-month follow-up and later were higher but not statistically significantly dif-
ferent compared to baseline. African-American patients reported higher fatigue post-SBRT
than Caucasian patients. Fatigue was correlated with hormonal symptoms as measured
by the Expanded Prostate Cancer Index Composite (EPIC) quality of life questionnaire,
but not with urinary, bowel, or sexual symptoms. Age, co-morbidities, smoking, prostate
specific antigen (PSA) levels, testosterone levels, tumor stage, and treatment variables
were not associated with fatigue. Conclusion:This is the first study to investigate fatigue
as a side effect of SBRT. In contrast to standard radiation therapy, results suggest SBRT-
related fatigue is short-term rather than a long-term side effect of SBRT.These results also
suggest post-SBRT fatigue to be a more frequent complication in African-Americans than
Caucasians.
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INTRODUCTION
Fatigue limits a patient’s ability to care for themselves and decreases
their quality of life (Hickok et al., 2005; Ryan et al., 2007). Unfortu-
nately, fatigue is a common radiation therapy side effect (Jereczek-
Fossa et al., 2002) even in patients with localized prostate cancer
(Walker et al., 1996). Currently, the etiology of radiation therapy-
related fatigue is poorly understood and likely multi-factorial
(Ryan et al., 2007). Typically, fatigue begins shortly after the ini-
tiation of treatment and can take months to resolve following
the completion of treatment (Hickok et al., 2005; Kyrdalen et al.,
2010). Chronic fatigue can occur and may be related to patient spe-
cific factors or treatment-related side effects (Ryan et al., 2007).
Radiation-induced fatigue is treatment volume-dependent with
larger fields causing increased fatigue (Beard et al., 1997). The
level of fatigue is also dependent on the treatment site, with pelvic
irradiation inducing testosterone reductions that may be partially
responsible for radiation-induced fatigue (Pickles and Graham,
2002; Oermann et al., 2011).
Standard radiation therapy for clinically localized prostate can-
cer entails 8–9 weeks of daily low dose (1.8–2.0 Gy fractions)
radiation. This demanding schedule possibly induces fatigue inde-
pendent of treatment. Recently, large radiation fraction sizes have
been shown to be radiobiologically favorable compared to smaller
fraction sizes in prostate cancer radiotherapy (Fowler, 2005).
Typically, hypofractionated stereotactic body radiation therapy
(SBRT) delivers 35–40 Gy to the prostate in four to five fractions.
CyberKnife (Accuray, Inc., Sunnyvale, CA, USA) seems ideal for
delivering hypofractionated SBRT with its sub-millimeter accu-
racy (Kilby et al., 2010). Unlike standard radiation therapy delivery
systems, the CyberKnife incorporates a real-time motion tracking
system that provides updated target position and corrects the tar-
geting of the therapeutic beam during treatment. Intrafraction
motion tracking allows for a reduction in the planning target
volume (PTV) and potentially the dose to surrounding critical
organs. These abilities allow for dose escalation within the prostate
while maintaining normal tissue tolerance and thereby reducing
potential side effects of radiation therapy.
Published outcomes for CyberKnife delivered SBRT suggest
high biochemical control rates with acceptable toxicity a few years
following treatment (King et al., 2003, 2009; Fuller et al., 2008;
Friedland et al., 2009; Katz et al., 2010; Oermann et al., 2011; Jab-
bari et al., 2012). Indeed, recent updates have confirmed a 5-year
biochemical disease-free survival in excess of 90% (Freeman and
King, 2011; King et al., 2012). In addition, early quality of life
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data indicate that SBRT is well tolerated with declines in patient
reported urinary, bowel, and sexual function similar to other radi-
ation therapy treatments (Sanda et al., 2008). We hypothesize that
reducing the length of treatment and treatment volumes, could
reduce treatment-related fatigue. In this study of prostate cancer
patients undergoing hypofractionated SBRT, we evaluated cancer-
related fatigue at baseline (prior to treatment) and at 1, 3, 6, 9, and
12 months post-treatment.
MATERIALS AND METHODS
STUDY POPULATION
Patients included in this retrospective Medstar-Georgetown Uni-
versity institutional review board approved study were treated and
followed-up from January 2010 to November 2011 with hypofrac-
tionated SBRT for clinically localized prostate adenocarcinoma.
The patient eligibility criteria were: (1) histologically confirmed
prostate cancer; (2) age 75 or less; (3) a minimum of 12 months
follow-up; and (4) completion of the Functional Assessment
of Cancer Therapy (FACIT)-Fatigue survey (Cella et al., 1993;
Lai et al., 2003; Davis et al., 2008), Expanded Prostate Cancer
Index Composite (EPIC-26; Wei et al., 2000), and the American
Urological Association (AUA) prostate symptom questionnaires.
Informed consent was obtained from all participants prior to
participation in the study.
TREATMENT
All patients received CyberKnife delivered SBRT as previously
described (Oermann et al., 2011). Briefly, a linear accelerator
mounted on a flexible robotic arm delivered a few hundred unique
treatment beams in a non-isocentric manner via circular collima-
tors. The gross tumor volume (GTV) included the prostate and the
proximal seminal vesicles. The PTV equaled the GTV expanded
3 mm posteriorly and 5 mm in all other dimensions. The pre-
scribed dose was 35 or 36.25 Gy in five fractions of 7–7.25 Gy over
1–2 weeks. The prescription isodose line was limited to >75%.
ASSESSMENTS
Patients were evaluated at 1, 3, 6, 9, and 12 months post-SBRT.
Prostate specific antigen (PSA) and testosterone levels were
recorded, toxicity assessed, and fatigue and health related quality
of life (HRQOL) questionnaires completed at baseline and each
follow-up. Fatigue was measured using the FACIT-Fatigue survey
managed and distributed by FACIT.org1 The FACIT-Fatigue is a
13-item subscale developed to identify a finite set of concerns spe-
cific to fatigue. Fatigue scores for the 13-item fatigue scale range
from 0 to 52, where lower scores indicate low energy or higher
fatigue. Similarly, higher scores indicate higher energy and lower
fatigue.
Health related quality of life (HRQOL) was measured using
two instruments – the EPIC-26 survey and the AUA prostate
symptom survey. The EPIC-26 is a 26-item short form version
of the original EPIC survey designed to evaluate patient function
and bother after prostate cancer treatment (Wei et al., 2000). The
survey asks questions and provides a score associated with the fol-
lowing five domains of HRQOL specific to prostate cancer therapy:
1www.facit.org.
urinary irritative/obstructive, urinary incontinence, bowel, sexual,
and hormonal domains.
The AUA prostate symptom index is prostate function survey
developed and validated by the Multidisciplinary Measurements
Committee of the AUA. The 7-item survey assesses non-specific
urinary symptoms (incomplete emptying, frequency, intermit-
tency, urgency, weak stream, straining, and nocturia) associated
with clinical benign prostatic hypertrophy. A high score indicates
greater symptom bother and lower HRQOL.
In addition to information on fatigue and HRQOL, data on the
following covariates were also collected: age, race, co-morbidities
including history of HIV and other cancers, smoking status, PSA
levels, testosterone levels, AJCC/UICC TNM stage, and Gleason
score.
Statistical analysis
Baseline characteristics of the study participants were summarized
using frequencies and means. Fatigue scores (FACIT-Fatigue scale)
were calculated using guidelines provided by the FACIT Measure-
ment System (FACIT.org). Domain scores for the EPIC-26 survey
were calculated using the information provided in the University
of Michigan’s EPIC website2. AUA symptom score was calculated
by summing the responses for the 7 items in the score for each
participant.
Correlations between the FACIT-Fatigue scores and the
HRQOL measures were tested using non-parametric (Spearman
correlation coefficient) methods. Associations of fatigue scores
prior to SBRT (at baseline) with selected variables (age, race, smok-
ing status, HIV status, other cancer diagnosis, tumor stage, PSA
at baseline, and testosterone levels at baseline) were investigated
using multiple linear regression models. Linear generalized esti-
mating equations (GEE) models were used to determine whether
post-SBRT fatigue scores (at 1, 3, 6, 9, and 12 months post- treat-
ment) were significantly different from baseline scores. Repeat
fatigue score measurements for an individual over time were
accounted for using an autoregressive model of correlation that
assumes a higher degree of correlation between measurements
conducted closer in time than those that are farther apart. The
age-adjusted fatigue scores were derived using the least square
means in the GEE models that included age as a fixed effect.
P-values for the difference between pre- and post-SBRT fatigue
scores were adjusted for the following covariates: age, race, co-
morbidities including history of HIV and other cancers, smoking
status, PSA levels, testosterone levels, and tumor stage. Clinical sig-
nificance of the change in scores from baseline at each follow-up
visit was defined as change exceeding half the standard devia-
tion of the baseline score. The GEE models were further stratified
by race (African-American and Caucasian) to determine whether
there was any evidence of effect modification by these variables
on the fatigue scores pre- and post-SBRT. Statistical significance
of the effect modification by race was determined by including
a multiplicative (race× treatment) variable in the GEE model.
All statistical analyses were conducted using SAS v. 9.3 (SAS
Systems, Inc.).
2http://www.med.umich.edu/urology/research/EPIC/EPIC-26-Scoring-
1.2007.pdf.
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RESULTS
Forty patients with a minimum of 12 months follow-up met
the eligibility criteria and are the subject of this analysis. The
patient characteristics are presented in Table 1. The majority of
the patients were either African-American (50%) or Caucasian
(45%). Although all patients reported some type of co-morbidity,
only 2 (4%) were HIV positive and 4 (10%) reported a history
of second cancer in addition to the prostate cancer. The majority
of the patients were non-smokers (75%). As expected, given the
tumor stage eligibility for SBRT therapy, all patients were either
clinically T1 (65%) or T2(35%) at the time of diagnosis. The
majority of patients (94%) had Gleason scores of 6 (45%) or 7
(49%); 1 (3%) patient had Gleason scores of 8. Mean baseline PSA
and testosterone at diagnosis were 10.05 ng/ml and 279.26 ng/dL,
respectively. Treatment variables are presented in Table 2.
Overall questionnaire completion compliance was greater than
95%. No association with baseline fatigue scores was found
Table 1 | Patient characteristics.
Characteristic N (%)
Age, in years; mean (SD) 70.13 (6.60)
Race
Caucasian 18 (45)
African-American 20 (50)
Other 2 (5)
Smoker
No 30 (75)
Yes 10 (25)
HIV positive
No 38 (95)
Yes 2 (5)
Other cancer
No 36 (90)
Yes 4 (10)
Tumor stage*
T1c 26 (65)
T2a 8 (20)
T2b 4 (10)
T2c 2 (5)
Gleason score
2+3 1 (3)
3+3 18 (45)
3+4 14 (35)
4+3 6 (14)
4+4 1 (3)
PSA at baseline, in ng/ml; mean (SD) 10.05 (22.93)
PSA at baseline (ng/ml)
<10 34 (85)
10–20 5 (13)
≥20 1 (2)
Testosterone at baseline, in ng/dL; mean (SD) 279.26 (176.32)
SD, standard deviation; PSA, prostate specific antigen. *Nodal (N) and metas-
tasis (M) status could not be evaluated for 85% of the participants and are not
presented.
between age, race, smoking status, HIV status, history of another
cancer in addition to prostate cancer, baseline testosterone lev-
els, or tumor stage. Baseline PSA levels and fatigue scores were
statistically significantly associated (P= 0.05) with a higher base-
line PSA level associated with a lower FACIT-Fatigue score (higher
fatigue). Analysis of correlations between fatigue scores with the
HRQOL measures (EPIC-26 domains and AUA symptom score)
identified the EPIC hormone domain as the only HRQOL score
significantly correlated with the FACIT-Fatigue score (Spearman
ρ= 0.69,P< 0.0001). Lower FACIT-Fatigue scores were associated
with higher reported HRQOL in the EPIC hormone domain.
Age-adjusted mean FACIT-Fatigue scores at baseline and dur-
ing follow-up after CyberKnife SBRT are presented in Table 3. The
mean fatigue was statistically significantly higher (lower FACIT-
Fatigue scores) at the 1-month post-SBRT follow-up compared to
baseline. However, the change in fatigue scores was not clinically
significant as determined by greater than one-half of a standard
deviation change from baseline FACIT-Fatigue scores. Although
FACIT-Fatigue scores were lower at the 3, 6, 9, and 12 month
follow-up visits compared to baseline, none of the differences were
either clinically or statistically significant.
The impact of race on the change in FACIT-Fatigue scores
post-SBRT was compared to baseline by stratifying the age-
adjusted fatigue scores by race (Figure 1). Given that the majority
Table 2 |Treatment variables.
Characteristic N (%)
Total SBRT dose (Gy), Mean (SD)
35.00 8 (20)
36.25 32 (80)
Isodose line (%), mean (SD) 77 (1)
Total non-zero beams, mean (SD) 249 (20)
PTV (cm3), mean (SD) 168 (43)
GTV (cm3), mean (SD) 88 (29)
Total monitor unit (MU), mean (SD) 57,285 (8,549)
SBRT, stereotactic body radiation therapy; PTV, planning tumor volume; GTV,
gross tumor volume.
Table 3 | Age-adjusted pre- and post-SBRT fatigue scores.
Facit-fatigue score Mean (SE)* P change from pre-SBRT#
Pre-SBRT 43.78 (1.43) −
Post-SBRT (Month)
1 40.66 (1.43) 0.02
3 42.81 (1.43) 0.37
6 43.07 (1.45) 0.87
9 41.13 (1.45) 0.40
12 43.18 (1.43) 0.61
SBRT, stereotactic body radiation therapy; SE, standard error.
*Age-adjusted least square means.
#P-values adjusted for age, race, smoking status, tumor stage, HIV status, other
cancer diagnosis, baseline PSA values, and baseline testosterone values.
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FIGURE 1 | Age-adjusted fatigue and EPIC hormone domain scores in
Caucasians and African-Americans. Dashed lines represent half standard
deviation above and below the baseline scores. Change greater than half
standard deviation suggests clinical significance. **Change from baseline
statistically significant at <0.01 level. *Change from baseline statistically
significant at <0.05 level.
(95%) of patients were either African-American or Caucasian, we
restricted the stratified analysis to these races. Although Cau-
casian patients reported lower fatigue at baseline [44.1 (9.8)]
compared to African-Americans [43.5 (7.1)] the differences were
not statistically significant (P = 0.22).
At the 1-month post-SBRT, a statistically and clinically sig-
nificant increase in fatigue was observed for African-American
patients but not for Caucasian patients. In addition, the 12-
month post-SBRT FACIT-Fatigue score for Caucasian patients
was slightly higher than the pre-treatment score but for African-
Americans post-SBRT fatigue scores consistently remained low
compared to the baseline.
The results of the EPIC hormone domain analysis were similar
to the race-stratified results for FACIT-Fatigue scores (Figure 1).
African-American patients were more likely to report a lower
HRQOL on the hormone domain following SBRT than Caucasian
patients. The difference in the hormone score was statistically
and clinically significant between baseline and 1-month follow-
up for African-American patients but not for Caucasian patients.
In the multivariate models, only SBRT was significantly associ-
ated with fatigue. Age, co-morbidities including history of HIV
and other cancers, smoking status, PSA levels, testosterone lev-
els, tumor stage, and treatment variables were not associated with
FACIT-Fatigue scores after adjusting for SBRT.
DISCUSSION
Fatigue was not a major side effect for prostate cancer patients
undergoing hypofractionated SBRT. Although fatigue at 1-month
post-SBRT was higher than baseline, the change was not clinically
significant. Additionally, levels of fatigue at 3, 6, 9, and 12-month
post-SBRT were not significantly different from baseline. How-
ever, a racial disparity in fatigue following SBRT was present with
African-American patients reporting increased treatment-related
fatigue compared to Caucasian patients.
This is the first study to measure SBRT-related fatigue using the
FACIT-Fatigue scale. The level of fatigue reported at baseline by
prostate cancer patients [Mean (SD): 43.8 (8.2)] is very similar to
that reported for the general US population [43.6 (9.4); Cella et al.,
2002]. There was also no appreciable difference in baseline mean
fatigue scores between Caucasian and African-Americans. Fatigue
at 1-month post-SBRT in this patient population was very similar
to what has been reported for non-anemic cancer patients [40.6
vs. 40.0; Cella et al., 2002].
Acute increases in fatigue following radiotherapy for prostate
cancer have been previously reported (Stone et al., 2001; Hickok
et al., 2005; Danjoux et al., 2007). The current results support the
findings from previous studies that suggest fatigue peaks at 4–
6 weeks after the initiation of radiation therapy. In most cases,
these increases correspond to the completion of the extended
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radiotherapy regimen. However, hypofractionated SBRT treat-
ment in the current study has a short, 1–2 week treatment dura-
tion. A limitation of this study is that fatigue levels were not
measured at the end of SBRT. Thus, it is not known how fatigue lev-
els at 1 week after SBRT initiation compare with those at 1-month
post-SBRT. In addition, previous studies used scales other than
FACIT-Fatigue to measure fatigue which limits direct comparison
with our the results.
Long term fatigue was not observed in patients treated with
SBRT. At 3 months follow-up fatigue among both Caucasian and
African-American patients had returned to near baseline scores.
Although there is some evidence that definitive radiotherapy is
associated with long-term fatigue (at 12 months or more post-
radiotherapy; Kyrdalen et al., 2010) studies looking at modern
radiotherapy methods, such as intensity-modulated radiotherapy
(IMRT) have not shown any lasting effects on fatigue or HRQOL
measures (Marchand et al., 2010).
Previous studies have also reported that fatigue is associated
with and has an impact on HRQOL (Rodrigues et al., 2004; Monga
et al., 2005; Truong et al., 2006). For SBRT, no association or
correlation of FACIT-Fatigue scores with the urinary, sexual, and
bowel domains of EPIC-26 or with the AUA symptom score were
observed. However, a strong positive correlation was observed
for hormonal symptoms reported on EPIC-26 and the FACIT-
Fatigue score. It is not clear if this is due to a hormonal basis for
radiation-induced fatigue or a result of a similar item (“lack of
energy” in EPIC and “I have energy” in FACIT-Fatigue) on both
questionnaires. While small declines in testosterone levels have
been reported following hypofractionated SBRT (Oermann et al.,
2011), neither biochemical nor clinical hypogonadism appeared to
result from the changes in testosterone level. Larger sample sizes
are required to validate these observations.
Strengths of this study include a high proportion of African-
Americans in the patient population, multiple follow-up intervals
after SBRT, and use of validated instruments to measure fatigue
and HRQOL. The FACIT-Fatigue Scale is a brief and easy to use
measure of fatigue assessing the intensity of fatigue and the impact
on a patient’s daily life. It distinguishes itself psychometrically from
other measures as cutoff scores have been developed to aid in clini-
cal interpretation. Additionally, raw scores have been transformed
to a 0–100 interval measure which aids in the analysis of group
differences assessing change over time as in the present study.
Limitations of this study include the number of partici-
pants, pre-existing co-morbidities and possible variation in patient
lifestyle. Specifically, the statistical power was inadequate to ana-
lyze associations between fatigue and other baseline variables, such
as PSA levels and tumor stage. In addition, almost all prostate
cancer patients in our study had some co-morbidity, most fre-
quently cardiovascular, and it is unknown whether changes in
fatigue might have been associated with those co-morbidities.
Nevertheless, the mean fatigue scores at baseline in our patient
population were very similar to the general US population, thus it
is unlikely that co-morbidities affected the reporting of fatigue lev-
els. The multivariate analyses were adjusted for co-morbidities and
none of the reported co-morbidities were associated with fatigue.
Lastly, it is well known that lifestyle factors such as diet and exer-
cise affect fatigue; however, lifestyle factors were not factored into
the multivariate models.
A low incidence of fatigue was observed in prostate cancer
patients undergoing hypofractionated SBRT. Reported fatigue
was highest at 1 month post-SBRT, primarily among African-
American patients. At 12 months post-SBRT fatigue levels for both
Caucasians and African-American patients returned to near base-
line levels. More studies with additional patients are needed to
confirm these findings and investigate whether racial disparity is
a component of fatigue following SBRT for prostate cancer.
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